NASDAQ:EYEN Eyenovia Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyenovia Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.39 -0.02 (-0.59 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$3.35Now: $3.39▼$3.4550-Day Range$3.40MA: $3.74▼$5.1052-Week Range$1.11Now: $3.39▼$6.92Volume162,516 shsAverage Volume462,005 shsMarket Capitalization$69.62 millionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Eyenovia has a forecasted upside of 283.5% from its current price of $3.39.Amount of Analyst CoverageEyenovia has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesEyenovia has received 139 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEyenovia has received 161 “underperform” votes. (Add your “underperform” vote.)Community SentimentEyenovia has received 53.67% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote “Outperform” if you believe EYEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,198,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 23.50% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 6.30% of the stock of Eyenovia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to decrease in the coming year, from ($0.99) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.74 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEN Previous Symbol CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone917-289-1117Debt Debt-to-Equity Ratio0.04 Current Ratio3.99 Quick Ratio3.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book4.77Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-21,160,000.00 Net MarginsN/A Return on Equity-166.90% Return on Assets-135.90%Miscellaneous EmployeesN/A Outstanding Shares20,536,000Market Cap$69.62 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $3.39 -0.02 (-0.59 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EYEN News and Ratings via Email Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Eyenovia (NASDAQ:EYEN) Frequently Asked Questions How has Eyenovia's stock price been impacted by Coronavirus? Eyenovia's stock was trading at $2.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EYEN stock has increased by 16.9% and is now trading at $3.39. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Eyenovia? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyenovia. When is Eyenovia's next earnings date? Eyenovia is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Eyenovia. How were Eyenovia's earnings last quarter? Eyenovia Inc (NASDAQ:EYEN) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.04. View Eyenovia's earnings history. What price target have analysts set for EYEN? 4 brokers have issued twelve-month target prices for Eyenovia's stock. Their forecasts range from $7.00 to $19.00. On average, they expect Eyenovia's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 283.5% from the stock's current price. View analysts' price targets for Eyenovia. Are investors shorting Eyenovia? Eyenovia saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 214,800 shares, a decrease of 51.9% from the August 15th total of 446,700 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is presently 0.2 days. Approximately 1.7% of the company's stock are short sold. View Eyenovia's Short Interest. Who are some of Eyenovia's key competitors? Some companies that are related to Eyenovia include Immunic (IMUX), ProQR Therapeutics (PRQR), Calithera Biosciences (CALA), NextCure (NXTC), Arbutus Biopharma (ABUS), Lannett (LCI), MediciNova (MNOV), Tiziana Life Sciences (TLSA), Cassava Sciences (SAVA), Verrica Pharmaceuticals (VRCA), Kalvista Pharmaceuticals (KALV), Nature's Sunshine Products (NATR), Hookipa Pharma (HOOK), Verastem (VSTM) and Fulcrum Therapeutics (FULC). View all competitors. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), Axsome Therapeutics (AXSM), Opko Health (OPK), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Albireo Pharma (ALBO), Leap Therapeutics (LPTX), Matinas BioPharma (MTNB), Zynerba Pharmaceuticals (ZYNE) and Aldeyra Therapeutics (ALDX). Who are Eyenovia's key executives? Eyenovia's management team includes the following people: Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)Mr. Luke Clauson, VP of R&D (Age 40)Mr. John P. Gandolfo, CFO & Sec. (Age 58)Mr. Michael M. Rowe, VP of Marketing When did Eyenovia IPO? (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. What is Eyenovia's stock symbol? Eyenovia trades on the NASDAQ under the ticker symbol "EYEN." Who are Eyenovia's major shareholders? Eyenovia's stock is owned by many different institutional and retail investors. Top institutional shareholders include Uniplan Investment Counsel Inc. (2.99%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Curt H Labelle, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View institutional ownership trends for Eyenovia. Which institutional investors are selling Eyenovia stock? EYEN stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc.. View insider buying and selling activity for Eyenovia. How do I buy shares of Eyenovia? Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eyenovia's stock price today? One share of EYEN stock can currently be purchased for approximately $3.39. How big of a company is Eyenovia? Eyenovia has a market capitalization of $69.62 million. The company earns $-21,160,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. What is Eyenovia's official website? The official website for Eyenovia is www.eyenoviabio.com. How can I contact Eyenovia? Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
